Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $215M | $302M | $409M | $393M | $520M | $580M | $667M | $608M | $662M | $719M |
| Revenue growth | — | 40.6% | 35.3% | -3.9% | 32.5% | 11.4% | 15.1% | -8.9% | 8.9% | 8.6% |
| Operating income | $54.2M | $99.5M | $144M | $149M | $174M | $86.0M | $46.1M | -$5.27M | $81.7M | -$62.3M |
| Operating margin | 25.2% | 32.9% | 35.3% | 37.8% | 33.4% | 14.8% | 6.9% | -0.9% | 12.3% | -8.7% |
| Net income | $91.2M | $57.3M | $111M | $113M | $127M | $53.4M | $60.7M | $1.32M | $73.9M | -$38.5M |
| Net margin | 42.4% | 19.0% | 27.1% | 28.8% | 24.4% | 9.2% | 9.1% | 0.2% | 11.2% | -5.4% |
| EPS (diluted) | $1.76 | $1.08 | $2.05 | $2.10 | $2.36 | $0.98 | $1.04 | $0.02 | $1.32 | -$0.68 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $66.8M | $115M | $129M | $143M | $138M | $127M | $117M | $111M | $172M | $47.3M |
| Capital expenditures | $1.60M | $2.03M | $844K | $2.74M | $3.45M | — | $412K | $551K | $725K | $1.34M |
| Free cash flow | $65.2M | $113M | $128M | $140M | $135M | — | $116M | $111M | $171M | $46.0M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $66.4M | $100M | $192M | $181M | $289M | $203M | $93.1M | $75.1M | $69.3M | $128M |
| Total assets | $310M | $424M | $978M | $1.16B | $1.50B | $1.69B | $1.70B | $1.28B | $1.37B | $1.45B |
| Total liabilities | $118M | $157M | $525M | $565M | $759M | $873M | $816M | $356M | $332M | $391M |
| Shareholders' equity | $192M | $267M | $453M | $595M | $745M | $816M | $886M | $922M | $1.04B | $1.06B |
| Retained earnings | -$84.3M | -$26.8M | $86.5M | $200M | $326M | $380M | $481M | $483M | $556M | $518M |
| Shares (wtd avg diluted) | 51.7M | 53.3M | 54.1M | 53.8M | 53.7M | 54.4M | 61.7M | 55.5M | 56.0M | 56.5M |
Every figure is extracted from SUPERNUS PHARMACEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.